Barclays Sees Regeneron Undervalued as Dupixent and Pipeline Drive Future Earnings
Barclays initiated coverage of Regeneron Pharmaceuticals with an Overweight rating and set a $923 price target, arguing the market is underestimating the company’s near- and medium-term profit potential from Dupixent and the broader drug pipeline. The broker highlighted continuing new indications for Dupixent, durability of intellectual property pr…